Kidney Disease
Keryx Biopharmaceuticals Inc.
Keryx Biopharmaceuticals Inc. announced top-line results from its SUN-MICRO Phase 3 clinical trial of Sulonex (sulodexide) for the treatment of diabetic nephropathy.
Prometic Life Sciences Inc.
ProMetic Life Sciences Inc. announced favorable top-line findings from the third cohort in its Phase II trial with PBI-1402 in patients with chemotherapy-induced anemia. Analysis of the compiled data from a total of 18 patients showed an overall statistically significant increase of the mean hematocrit values at weeks 4, 6 and 8, and of the hemoglobin values at week 8. At week 8, p values were 0.02 for hematocrit and hemoglobin.
The Journal of the American Society of Nephrology
The following articles were recently published in The Journal of the American Society of Nephrology:
In acute kidney failure, a cell-filled device temporarily replaced the injured cells and cut death rates significantly...
In acute kidney failure, a cell-filled device temporarily replaced the injured cells and cut death rates significantly, according to a preliminary study.
Action Points: 1.) Explain to patients who ask that a preliminary study found that treatment with an external kidney-assist device in addition to standard therapy improved outcomes for high-risk patients with acute kidney failure.
$125 million nationwide settlement in the average wholesale price (AWP) litigation filed in 2002 by consumers and insurance co.
Abbott Laboratories, Amgen Inc., Aventis Pharmaceuticals Inc., Bayer Corporation, Dey, Inc., Pharmacia Corporation, Pharmacia & Upjohn LLC, SICOR, Inc., SICOR Pharmaceuticals, Inc., Watson Pharmaceuticals Inc., CSL Behring LLC, Hoechst Marion Roussel and Baxter Healthcare Corporation agreed to a $125 million nationwide settlement in the average wholesale price (AWP) litigation filed in 2002 by consumers and insurance companies, which claimed the defendants intentionally inflated reports of the average wholesale prices on certain prescription dr
Amgen Inc.
Amgen Inc. announced the U.S. Food and Drug Administration has approved updated safety information, including an updated boxed warning in the labeling information for the class of drugs known as erythropoiesis-stimulating agents (ESAs), including Aranesp(R) (darbepoetin alfa) and EPOGEN(R) (Epoetin alfa).
Rockwell Medical Technologies Inc
Rockwell Medical Technologies Inc. reported record fourth quarter 2007 sales of $11.95 million, up 29.5% as compared to $9.2 million for the same period of 2006. Loss for the fourth quarter was $1,162,843 or $0.09 per share compared with $1,155,035 or $0.10 for the same period of 2006.
- Login to post comments
PDL BioPharma Inc.
PDL BioPharma Inc. reported earnings results for the fourth quarter and full year ended December 31, 2007. Total revenues for the fourth quarter of 2007 were $49.8 million compared to $59.8 million in the same period of 2006.
Cantel Medical Corp.
Cantel Medical Corp. reported earnings results for the second quarter ended January 31, 2008. For the quarter, the Company reported net income of $2,157,000 or $0.13 per diluted share, on net sales of $60,910,000 compared to net income of $2,270,000 or $0.14 per diluted share, on net sales of $51,635,000 for the same period last year.
- Login to post comments
PDL BioPharma Inc
#1 PDL BioPharma Inc. said it will stop pursuing the sale of the company or its biotechnology assets after a firm offer failed to emerge, sending its shares down nearly 19% in extended trading. The company said it now plans to cut 260 jobs and restructure to focus on discovery and development of antibody-based drugs.
